title: A real - life observational pilot study to evaluate the effects of two-week treatment with montelukast in patients with chronic cough.
abstract: BACKGROUND
  Different conditions make the proximal airways susceptible to tussigenic stimuli in the chronic cough (CC) syndrome. Leukotrienes can be implicated in the inflammatory mechanism at play in it. Montelukast is a selective cysteinyl-leukotriene receptor antagonist with proven effectiveness in patients with asthma. The aim of our real-life pilot study was to use montelukast to relieve cough symptoms in patients with CC allegedly due to the two frequent causes other than asthma - upper airway cough syndrome and gastroesophageal reflux (GER).
  
  
  METHODS
  14 consecutive patients with CC were evaluated before and after 2 weeks of treatment with montelukast 10 mg daily. Cough was assessed by validated cough questionnaire. Questionnaires regarding the presence of gastroesophageal reflux were also completed. Cough reflex sensitivity to incremental doubling concentrations of citric acid and capsaicin was measured. Lung function, airway hyperresponsiveness and exhaled breath temperature (EBT), a non-invasive marker of lower airway inflammation, were evaluated to exclude asthma as an underlying cause. Thorough upper-airway examination was also conducted. Cell counts, eosinophil cationic protein (ECP), lactoferrin, myeloperoxidase (MPO) were determined in blood to assess systemic inflammation.
  
  
  RESULTS
  Discomfort due to cough was significantly reduced after treatment (P < 0.001). Cough threshold for capsaicin increased significantly (P = 0.001) but not for citric acid. The values of lactoferrin and ECP were significantly reduced, but those of MPO rose. EBT and pulmonary function were not significantly affected by the treatment.
  
  
  CONCLUSIONS
  Patients with CC due to upper airway cough syndrome or gastroesophageal reflux (GER) but not asthma reported significant relief of their symptoms after two weeks of treatment with montelukast. ECP, lactoferrin, MPO altered significantly, highlighting their role in the pathological mechanisms in CC. Clinical trial ID at Clinicaltrials.gov is NCT01754220.
authors.forename: Roxana K
authors.initials: RK
authors.lastname: Mincheva
authors.forename: Tanya Z
authors.initials: TZ
authors.lastname: Kralimarkova
authors.forename: Miroslava
authors.initials: M
authors.lastname: Rasheva
authors.forename: Zlatko
authors.initials: Z
authors.lastname: Dimitrov
authors.forename: Denislava
authors.initials: D
authors.lastname: Nedeva
authors.forename: Maria
authors.initials: M
authors.lastname: Staevska
authors.forename: Vera
authors.initials: V
authors.lastname: Papochieva
authors.forename: Penka
authors.initials: P
authors.lastname: Perenovska
authors.forename: Karina
authors.initials: K
authors.lastname: Bacheva
authors.forename: Vasil D
authors.initials: VD
authors.lastname: Dimitrov
authors.affiliation: Clinical centre of Allergy and Asthma, Alexander's University Hospital, 1 Georgi Sofyiski Str, 1431 Sofia, Bulgaria. ted.popov@gmail.com.
authors.forename: Todor A
authors.initials: TA
authors.lastname: Popov